prasinezumab (RG7935) / Roche 
Welcome,         Profile    Billing    Logout  
 9 Diseases   2 Trials   2 Trials   191 News 


12»
  • ||||||||||  prasinezumab (RG7935) / Roche
    Clinical, Journal:  Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. (Pubmed Central) -  Apr 22, 2024   
    This exploratory analysis suggests that, in a trial of 1-year duration, prasinezumab might reduce motor progression to a greater extent in individuals with more rapidly progressing Parkinson's disease. However, because this was a post hoc analysis, additional randomized clinical trials are needed to validate these findings.
  • ||||||||||  prasinezumab (RG7935) / Roche
    Investigating the mechanisms of antibody binding with alpha-synuclein for the treatment of Parkinson's Disease | Poster Board #820 (In-person; Poster Board #820; Hall C (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_9151;    
    Monoclonal antibodies (mAbs) are biological drugs with high specificity, and Prasinezumab (PRX002) is a mAb currently in Phase II, which targets the C-terminus (AA 118-126) of ?-syn...The mAb's developability was determined with computational screening methods. Our results demonstrate the efficiency and developability of this therapeutic agent.
  • ||||||||||  cinpanemab (BIIB054) / Biogen, prasinezumab (RG7935) / Roche, BAN0805 / BioArctic
    Journal, Gene Signature:  The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease. (Pubmed Central) -  Dec 27, 2023   
    Therapeutic drugs that target SNCA include ABBV-0805, Prasinezumab, Cinpanemab, and Gardenin A. The results of this study suggest that cellular DEF-MDRGs might play an important role in PD. AR, ISCU, SNCA, and PDK4 have the potential to be specific biomarkers for the early diagnosis of PD.
  • ||||||||||  Review, Journal:  Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches. (Pubmed Central) -  Oct 28, 2023   
    In this updated overview, we aim to cover the clinical aspects of the spectrum of PD-related cognitive impairment and discuss recent evidence on emerging treatment approaches that are under investigation at a preclinical and clinical level. Finally, we aim to provide additional insights and propose new ideas for investigation that may be feasible and effective for the spectrum of PD-related cognitive impairment.
  • ||||||||||  Review, Journal:  Single-neuron neurodegeneration as a degenerative model for Parkinson's disease. (Pubmed Central) -  Sep 18, 2023   
    In conclusion, based on the hypothesis that the neurodegenerative process of idiopathic Parkinson's disease corresponds to a single-neuron neurodegeneration model, we must search for molecules that increase the expression of the neuroprotective enzymes DT-diaphorase and glutathione transferase M2-2. It has been observed that the activation of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 pathway is associated with the transcriptional activation of the DT-diaphorase and glutathione transferase genes.
  • ||||||||||  prasinezumab (RG7935) / Roche
    PASADENA 1-year open-label extension () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1439;    
    P2
    It has been observed that the activation of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 pathway is associated with the transcriptional activation of the DT-diaphorase and glutathione transferase genes. Objective: To describe the results of PASADENA 1-year open-label extension (OLE).; Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential to slow disease progression in Parkinson
  • ||||||||||  prasinezumab (RG7935) / Roche
    Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1370;    
    Based on these results, we suggest that it is the heavy cerebral ?-synuclein deposition that is causally linked to the accelerated progression with cognitive decline in PD.; We will conduct a proof-of-concept multicenter, international, randomized, double-blind, placebo-controlled clinical trial to investigate the efficacy of the monoclonal anti-?-synuclein antibody Prasinezumab (F... This is the first proof-of-concept clinical trial in PD addressing cognitive decline with a modifying agent based on a clear biological stratification and applied in a clearly defined prodromal phase preceding dementia to overcome the big challenge in modifying treatments of being
  • ||||||||||  prasinezumab (RG7935) / Roche
    A New View on Quantification of Disease Modification: Two Case Studies from Parkinson () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_497;    
    Results from ADAGIO and PASADENA are inconclusive, due to differences in results across doses or outcomes. Regardless, estimation of time delays by methods such as the progression model for repeated measures could be helpful in quantifying disease-modifying aspects of treatments.
  • ||||||||||  prasinezumab (RG7935) / Roche, mesdopetam (IRL790) / Ipsen, tavapadon (CVL-751) / Cerevel Therap
    NEW INSIGHT IN THE TREATMENT OF PARKINSONS DISEASE (ONSITE - HALL F1+F2+F3) -  Dec 23, 2022 - Abstract #ADPD2023ADPD_877;    
    The PASADENA study tested prasinezumab and despite the primary end-point was not met positive signals were seen...The ORCHESTRA study with UCB0059, an oral Asyn antibody is also ongoing...A new dopamine agonist, tavapadon. Two different studies on dyskinesia are ongoing with a combination of buspirone and zolmitriptan and another with mesdopetam.
  • ||||||||||  prasinezumab (RG7935) / Roche
    Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies (Poster Station: GPT 12) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1039;    
    P2
    We demonstrated that C-terminal/C-terminal tandem peptide-based vaccine candidates provide superior attributes to both single-peptide vaccines and other tandem peptide vaccines we investigated in all assays: α-syn titers, pathological α-syn staining in human PD brains, and inhibition of α-syn aggregate internalization into a neuronal cell line. These preclinical data support clinical development of multi-peptide vaccines for the potential treatment and prevention of PD and other synucleinopathies.
  • ||||||||||  prasinezumab (RG7935) / Roche
    Estimating the Meaningful Within-Patient Change Threshold for the MDS-UPDRS Part III (Poster Station: 16) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_872;    
    P2, P2b
    These findings indicate that a 5-point increase on MDS-UPDRS Part III can be used as a threshold for meaningful worsening of motor signs. This supports the use of time-to-5-point increase on MDS-UPDRS Part III as the primary endpoint for the Phase IIb PADOVA study, an ongoing randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in early-stage PD (NCT04777331).
  • ||||||||||  prasinezumab (RG7935) / Roche
    Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III (Poster Station: GPT 6) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_780;    
    Progression in motor signs was larger under hypothetical compared with treatment policy strategy, suggesting a masking effect of symptomatic therapy. The consistent results under either estimand strategy suggest that a TTE analysis may mitigate the potential masking effect of symptomatic therapy on MDS-UPDRS Part III in PD.
  • ||||||||||  prasinezumab (RG7935) / Roche
    Journal:  Trial of Prasinezumab in Early-Stage Parkinson's Disease. (Pubmed Central) -  Aug 11, 2022   
    P2
    Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrials.gov number, NCT03100149.).
  • ||||||||||  prasinezumab (RG7935) / Roche
    ESTIMATING THE MEANINGFUL WITHIN-PATIENT CHANGE THRESHOLD FOR THE MDS-UPDRS PART III () -  Mar 9, 2022 - Abstract #ADPD2022ADPD_1726;    
    P2, P2b
    These findings indicate that a 5-point increase on MDS-UPDRS Part III can be used as a threshold for meaningful worsening of motor signs. This supports the use of time-to-5-point increase on MDS-UPDRS Part III as the primary endpoint for the Phase IIb PADOVA study, an ongoing randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in ePD (NCT04777331).
  • ||||||||||  prasinezumab (RG7935) / Roche
    Estimating the meaningful within-patient change threshold for the MDS-UPDRS Part III ([VIRTUAL]) -  Mar 6, 2022 - Abstract #AAN2022AAN_1807;    
    P2, P2b
    These findings indicate that a 5-point increase on MDS-UPDRS Part III can be used as a threshold for meaningful worsening of motor signs. This supports the use of time-to-5-point increase on MDS-UPDRS Part III as the primary endpoint for the Phase IIb PADOVA study, an ongoing randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in ePD (NCT04777331).
  • ||||||||||  cinpanemab (BIIB054) / Biogen, prasinezumab (RG7935) / Roche, MEDI1341 / AstraZeneca, Takeda
    Clinical, Journal:  Immunotherapies for Parkinson's disease: Progression of Clinical Development. (Pubmed Central) -  Feb 19, 2022   
    This approach shows some positive outcomes on the efficacy in removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson's disease. In this review, an overview of how alpha-synuclein contributes to Parkinson's disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.
  • ||||||||||  TREATMENT OF PARKINSON’S DISEASE: WHAT ABOUT THE NEXT FUTURE (ONSITE: 112) -  Dec 17, 2021 - Abstract #ADPD2022ADPD_279;    
    The ORCHESTRA study with UCB0059, an oral Asyn antibody is also recruiting...Two molecules are in clinical trials for GBA mutation, ambroxol and venglustat and one for patients with LRKK2 mutation, DNL151...Moreover to achive a more contnuos delivery of drug two subcutaneous preparation of levodopa are in clinical trials and olso an otal micropump able to deliver levodopa continuously. A new dopamine agonist, tavapadon and two drugs for dyskinesia are in clinical trial too.